Developmental funds have been used for two purposes during the last grant cycle and we propose to continue funding in these areas in the next grant cycle. 1) Pilot Funds - The CCSG developmental funds support three types of pilot grants, each targeting a different Cancer Center member group: ? Push grants - to accelerate (or """"""""push"""""""") the pace of effort on cancer-focused research initiatives judged to have a high potential to lead to peer-reviewed funding within 1 -2 years. Pull grants - to encourage cancer research among non-cancer members and new members, i.e. to """"""""puir them into the Cancer Center. Paff/7er grants - to encourage clinicians to partner with a basic or population scientist in a joint project in translational research. Partner grants require matching funds from the clinical department. These pilot grants have yielded a return of investment of about 14 fold over the past five years. We plan to continue using these pilot project mechanisms in the next grant cycle. 2) Shared Resource Development - We have used CCSG developmental funds from the past grant cycle to support our Crystallography and Computational Biosciences (CCB) shared resource. This shared resource was originally proposed in our last competing renewal and is now requested as a full shared resource. In the new grant cycle, we propose funding for two developing shared resources: Synthetic Chemistry and Translational Imaging. In addition to continuing funding for these two areas, we propose adding bridge funding support in the next grant cycle.

Public Health Relevance

Developmental funds provide a key source of support for the strategic and programmatic priorities and scientific opportunities of our Center as identified through our planning and evaluation processes. These funds provide the opportunity to explore innovative pilot projects, new collaborations and new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-39
Application #
8617231
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
39
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Mao, Chengqiong; Zhao, Yan; Li, Fang et al. (2018) P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 286:289-300
Xiao, Jiajie; Melvin, Ryan L; Salsbury Jr, Freddie R (2018) Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning. J Biomol Struct Dyn :1-18
Wang, Mingxuan; Chen, Haiqin; Ailati, Aisikaer et al. (2018) Substrate specificity and membrane topologies of the iron-containing ?3 and ?6 desaturases from Mortierella alpina. Appl Microbiol Biotechnol 102:211-223
Diaz-Garelli, Jose-Franck; Wells, Brian J; Yelton, Caleb et al. (2018) Biopsy Records Do Not Reduce Diagnosis Variability in Cancer Patient EHRs: Are We More Uncertain After Knowing? AMIA Jt Summits Transl Sci Proc 2017:72-80
Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :
Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182
Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79
Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162

Showing the most recent 10 out of 548 publications